An interventional study of Catheter ablation of atrial tachycardia: Ripple Mapping guided. and Catheter ablation of atrial tachycardia: Conventional mapping guided. in Atrial Tachycardia, sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 307 studies in Atrial Fibrillation with a site in United Kingdom — 42 open to participants now, 71 under way, 5 of them phase 3. Atrial Fibrillation · United Kingdom.
Among the 307 studies in Atrial Fibrillation with a site in United Kingdom, this one is the 86th largest by enrollment of the 207 interventional ones that give a count, is one of 22 that started in 2022, is one of 125 with no phase, and was the 182nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →42 of the 307 studies in Atrial Fibrillation with a site in United Kingdom are open now. Recruiting first, the newest first:
East Sussex Healthcare NHS Trust · Sites in United Kingdom
Ages 18+
University Hospitals Coventry and Warwickshire NHS Trust · Sites in United Kingdom
Ages 18+
Oslo University Hospital · Sites in United Kingdom, United States, Belgium and 7 more countries
Ages 18+
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 18–80
Liverpool John Moores University · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
307 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 37 · Phase 4 27
First in 1999; this study’s year is marked. 22 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 152 across the 207 interventional studies, 300 across the 99 observational. Of the 197 that completed or were terminated, 70 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
118 of 307 have an industry lead sponsor. The 10 most frequent:
Liverpool Heart and Chest Hospital NHS Foundation Trust is the lead sponsor of 33 studies on the registry; 6 are open to participants now.
Liverpool Heart and Chest Hospital NHS Foundation Trust has 9 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
20 of the studies in Atrial Fibrillation with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT06951100University of EdinburghMechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation | 2026-12 |
| NCT05777551Clinica MediterraneaAF Ablation With High Power Short Duration RF | 2026-12-31 |
| NCT07943065University Hospitals Coventry and Warwickshire NHS TrustA Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke Patients | 2027-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 307 studies in Atrial Fibrillation with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial tachycardia is a symptomatic arrhythmia, for which an effective treatment is a catheter ablation procedure. The goal of the Ripple AT-Plus study is to evaluate two methods of performing catheter ablation for atrial tachycardia. The main outcome assessed during the study is long-term recurrence of atrial tachycardia following the catheter ablation procedure.
Catheter based mapping of the electrical signals in the heart during atrial tachycardia can identify areas that require ablation in order to treat the arrhythmia. There are numerous methods by which to map atrial tachycardia. Isthmus guided ablation using Ripple Mapping is one such method, and has recently been demonstrated to improve diagnostic accuracy of mapping and therefore improve acute procedural outcomes (termination of the tachycardia).
However, it is not known if improved acute procedural outcomes translate into long-term benefits for patients. At present, the recurrence rate following atrial tachycardia ablation is near 30%. We hypothesise that isthmus guided ablation using Ripple Mapping can reduce long-term recurrence following ablation as improved diagnostic accuracy of mapping can lead to more targeted, less extensive, ablation.
Patients referred for catheter ablation of atrial tachycardia will be randomised to undergo the procedure by isthmus targeted approach using Ripple Mapping or conventional approach using local activation time. Otherwise, the catheters used to perform the mapping and ablation will be the same in both groups. After the procedure, follow up will occur at 1 year with a further Holter Montior. Any arrhythmia recurrence will be documented and the two arms will be compared for acute success, 12 month success, ablation required and procedure time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Isthmus targeted approach using Ripple Mapping catheter ablation of atrial tachycardia.
Procedure: Catheter ablation of atrial tachycardia: Ripple Mapping guided.
Intervention: conventional catheter ablation of atrial tachycardia.
Procedure: Catheter ablation of atrial tachycardia: Conventional mapping guided.
Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.
Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.
Atrial arrhythmia recurrence
Any confirmed episode of atrial arrhythmia (\>30 seconds on Holter or 12 lead ECG) occurring in the 12 months after catheter ablation.
Time frame: 12 months
Acute success during the catheter ablation procedure by the first ablation set.
Atrial tachycardia termination (acute success) during ablation delivered to only target the diagnosed AT mechanism by the mapping approach used (first ablation set).
Time frame: Procedure.
Acute success during the catheter ablation procedure without the need of entrainment.
Entrainment not required to confirm or exclude the diagnosis made by 3D electroanatomic mapping methods.
Time frame: Procedure.
Procedure failure.
Inability to terminate atrial tachycardia during the catheter ablation procedure, requiring external electrical cardioversion to achieve sinus rhythm.
Time frame: Procedure.
Total procedure time.
Procedure time measured from initiation of intracardiac mapping to catheter removal from the body.
Time frame: Procedure.
Ablation required
Ablation required, measured using pre-defined ablation index or ablation line length.
Time frame: Procedure.
Plan to share: No
Ran from Aug 2022 to primary completion in Jun 2025, 33 months.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 33 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Apr 2026 → Jun 2025 and completion Apr 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Liverpool Heart and Chest Hospital NHS Foundation Trust